SEC Form 10-K filed by Mirum Pharmaceuticals Inc.
$MIRM
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2026 | $130.00 | Outperform | RBC Capital Mkts |
| 9/24/2025 | $95.00 | Buy | TD Cowen |
| 8/11/2025 | $89.00 | Buy | Stifel |
| 5/19/2025 | $73.00 | Buy | H.C. Wainwright |
| 4/17/2024 | $48.00 | Buy | Stifel |
| 12/18/2023 | $60.00 → $58.00 | Buy | H.C. Wainwright |
| 11/20/2023 | $37.00 | Overweight | Analyst |
| 11/13/2023 | $60.00 | Overweight | Morgan Stanley |
RBC Capital Mkts initiated coverage of Mirum Pharmaceuticals with a rating of Outperform and set a new price target of $130.00
TD Cowen initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $95.00
Stifel resumed coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $89.00
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato
- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline data expected Q2 2026 - LIVMARLI® EXPAND study in additional cholestatic pruritus settings topline data expected Q4 2026 - Brelovitug AZURE-1 and AZURE-4 studies in HDV topline data expected H2 2026 - Conference call to provide business updates today, February 25 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financial results for the fourth quarter and year-end 2025 and provided a business update. "2025 was a year of meaningful progress and execution for
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference: Monday, March 2, 2026 Company fireside chat starting at 1:10 p.m. ET The Citizens Life Sciences Conference: Tuesday, March 10, 2026 Company fireside chat starting at 10:10 a.m. ET Barclays 28th Annual Global Healthcare Conference: Tuesday, March 10, 2026 2026 Leerink Partners Global Healthcare Conference: Wednesday, March 11, 2026 Company fireside chat starting at 10:00 a.m. ET The fireside chats will be webcast live and can be accessed by visiting th
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report fourth quarter and year-end 2025 financial results on February 25, 2026. Mirum will also host a conference call to discuss the fourth quarter and year-end 2025 financial results and recent corporate progress. Conference call details: Wednesday, February 25, 2026 4:30 p.m. ET / 1:30 p.m. PT Dial-In: US/Toll-Free: +1 833 470 1428 International: +1 646 844 6383 Access Code: 047642 You may also access the call via webcast by visiting the Investors section of Mirum's corporate website. The archived webcast will be available for replay. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals (NASDAQ:MIRM) is a
S-3ASR - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
S-8 - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
10-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv
- 2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones," said Chris
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline data expected Q2 2026 - LIVMARLI® EXPAND study in additional cholestatic pruritus settings topline data expected Q4 2026 - Brelovitug AZURE-1 and AZURE-4 studies in HDV topline data expected H2 2026 - Conference call to provide business updates today, February 25 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financial results for the fourth quarter and year-end 2025 and provided a business update. "2025 was a year of meaningful progress and execution for
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report fourth quarter and year-end 2025 financial results on February 25, 2026. Mirum will also host a conference call to discuss the fourth quarter and year-end 2025 financial results and recent corporate progress. Conference call details: Wednesday, February 25, 2026 4:30 p.m. ET / 1:30 p.m. PT Dial-In: US/Toll-Free: +1 833 470 1428 International: +1 646 844 6383 Access Code: 047642 You may also access the call via webcast by visiting the Investors section of Mirum's corporate website. The archived webcast will be available for replay. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals (NASDAQ:MIRM) is a
-Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations -Anticipated to be highly synergistic with Mirum's liver expertise and proven global commercial capabilities -HDV: Large, high unmet-need rare liver disease with no FDA-approved therapies -Top-line Phase 3 results expected in 2H 2026 -Conference call today, December 8, 2025 at 8:30 am ET/5:30 am PT Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldw